Classification and Scoring

Common Terminology Criteria for Adverse Events

The National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) developed the original Common Toxicity Criteria (CTC) in 1982 in an effort to provide a standard language for reporting adverse events occurring in cancer clinical trials sponsored by the NCI. CTC is widely accepted throughout the oncology research community as the standard grading scale for adverse events. The CTC has substantially evolved since its inception in 1982. The most recent version is the Common Terminology Criteria for Adverse Events (CTCAE) .1 The terminology provided for the grading of skin toxicity on this website includes the CTCAE, Version 4.0. Minor updates have been made to CTCAE v4.0, which are represented in v4.03. CTCAE v4.031 information is in the Public Domain and is available for public use. Despite its widespread use and its utility, the CTCAE has not been validated.

MASCC EGFR Inhibitor Skin Toxicity Tool© (MESTT)

The MESTT 2 was developed in 2008 by the MASCC Skin Toxicity Study Group as a tool to assist oncology health professions with the monitoring and reporting of dermatologic AEs in EGFRI-treated patients. The MESTT is an event-specific grading system that can be used to standardise assessment, optimise the use of EGFR inhibitors and enable researchers to conduct more informative, controlled studies in this patient population.


1National Cancer Institute Cancer Therapy Evaluation Program (CTEP). Common Toxicity Criteria for Adverse Events v4.03 (CTCAE) 2010. (accessed 22 August 2014)
2MASCC Guidelines and Assessment Tools (accessed 22 August 2014)

Last update: 22 August 2014